Arsenal Bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $220M
Overview
A programmable cell therapy company using CRISPR and synthetic biology to attack solid tumors.
Oncology
Technology Platform
A CRISPR-based synthetic biology platform for programming T-cells with multiple integrated functional modules to target solid tumors.
Funding History
1Total raised:$220M
Series B$220M
Opportunities
Could redefine cell therapy's applicability by successfully treating common solid tumors.
Risk Factors
Immense technical and manufacturing complexity, along with potential for severe immune-related toxicities.
Competitive Landscape
Competes with other advanced cell therapy engineering firms but is distinguished by its scale of genetic programming and computational integration.